{
    "title": "115_s2928",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Colorectal Cancer Detection Act of \n2018''.\n\nSEC. 2. MEDICARE COVERAGE FOR FDA-APPROVED QUALIFYING COLORECTAL CANCER \n              SCREENING BLOOD-BASED TESTS.\n\n    (a) In General.--Section 1861(pp) of the Social Security Act (42 \nU.S.C. 1395x(pp)) is amended--\n            (1) in paragraph (1)--\n                    (A) by redesignating subparagraph (D) as \n                subparagraph (E); and\n                    (B) by inserting after subparagraph (C) the \n                following new subparagraph:\n            ``(D) Qualifying colorectal cancer screening blood-based \n        test.''; and\n            (2) by adding at the end the following new paragraph:\n    ``(3) The term `qualifying colorectal cancer screening blood-based \ntest' means, with respect to a year, a screening blood-based test for \nthe early detection of colorectal cancer furnished in the year that was \nmarketed or used, as applicable, in accordance with the relevant \nprovisions of section 353 of the Public Health Service Act or the \nFederal Food, Drug, and Cosmetic Act more than 6 months before the \nbeginning of the year.''.\n    (b) Frequency Limits for Colorectal Cancer Screening Tests and \nPayment Amount for Qualifying Colorectal Cancer Screening Blood-Based \nTests.--Section 1834(d) of the Social Security Act (42 U.S.C. 1395m(d)) \nis amended--\n            (1) by amending clause (ii) of paragraph (1)(B) to read as \n        follows:\n                            ``(ii) if the test is performed within--\n                                    ``(I) the 11 months after a \n                                previous screening fecal-occult blood \n                                test or a previous qualifying \n                                colorectal cancer screening blood-based \n                                test;\n                                    ``(II) the 35 months after a \n                                previous screening flexible \n                                sigmoidoscopy or a previous screening \n                                colonoscopy with adenoma findings;\n                                    ``(III) the 59 months after a \n                                previous screening colonoscopy with \n                                small polyp findings; or\n                                    ``(IV) the 119 months after a \n                                previous screening colonoscopy without \n                                adenoma findings or small polyp \n                                findings.'';\n            (2) in paragraph (2)(E)(ii), by inserting ``or within the \n        35 months after a previous screening fecal-occult blood test or \n        previous qualifying colorectal cancer screening blood-based \n        test'' after ``sigmoidoscopy'';\n            (3) by amending subparagraph (E) of paragraph (3) to read \n        as follows:\n                    ``(E) Frequency limit.--No payment may be made \n                under this part for a colorectal cancer screening test \n                consisting of a screening colonoscopy--\n                            ``(i) if the procedure is performed within \n                        the 11 months after a previous screening fecal-\n                        occult blood test or previous qualifying \n                        colorectal cancer screening blood-based test;\n                            ``(ii) for individuals at high risk for \n                        colorectal cancer if the procedure is performed \n                        within the 23 months after a previous screening \n                        colonoscopy; or\n                            ``(iii) for individuals not at high risk \n                        for colorectal cancer if the procedure is \n                        performed within the 119 months after a \n                        previous screening colonoscopy or within the 47 \n                        months after a previous screening flexible \n                        sigmoidoscopy.''; and\n            (4) by adding at the end the following new paragraph:\n            ``(4) Qualifying colorectal cancer screening blood-based \n        tests.--\n                    ``(A) Payment amount.--The payment amount for \n                colorectal cancer screening tests consisting of \n                qualifying colorectal cancer screening blood-based \n                tests shall be established by the Secretary based on a \n                crosswalk to payment amounts for tests for the \n                diagnosis of inherited colorectal cancer by methylation \n                methods.\n                    ``(B) Frequency limit.--Paragraph (1)(B) shall \n                apply to colorectal cancer screening tests consisting \n                of qualifying colorectal cancer screening blood-based \n                tests in the same manner as such paragraph applies to \n                colorectal cancer screening tests consisting of fecal-\n                occult blood tests.''.\n    (c) Effective Date.--The amendments made by this section shall \napply to colorectal cancer screening tests furnished in a year \nbeginning more than 6 months after the date of the enactment of this \nAct."
}